Annovis Bio, Inc.
ANVS
$2.67
$0.208.10%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.99% | -32.64% | -43.89% | -1.83% | 12.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.12% | 69.45% | -19.21% | -19.55% | -35.50% |
| Operating Income | -44.12% | -69.45% | 19.21% | 19.55% | 35.50% |
| Income Before Tax | -67.69% | 42.53% | -23.90% | -418.99% | 73.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.69% | 42.53% | -23.90% | -418.99% | 73.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.69% | 42.53% | -23.90% | -418.99% | 73.60% |
| EBIT | -44.12% | -69.45% | 19.21% | 19.55% | 35.50% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 9.55% | 62.13% | 28.11% | -216.43% | 81.01% |
| Normalized Basic EPS | 9.56% | 62.12% | 28.11% | -216.08% | 81.01% |
| EPS Diluted | 19.53% | 62.01% | 27.93% | 55.39% | 78.65% |
| Normalized Diluted EPS | 9.56% | 62.12% | 28.11% | -222.24% | 81.01% |
| Average Basic Shares Outstanding | 85.43% | 51.71% | 72.33% | 64.06% | 38.99% |
| Average Diluted Shares Outstanding | 85.43% | 51.71% | 72.33% | 61.03% | 38.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |